Bristol-Myers Squibb Co_ logo on building-by tatu Campelo via iStock Sohini Mondal Mon, January 12, 2026 at 9:58 PM GMT+8 2 min read With a market cap of $113.7 billion, Bristol-Myers Squibb Company (BMY) is a global biopharmaceutical company that discovers, develops, manufactures, and markets innovative medicines for oncology, hematology, immunology, cardiovascular, and neuroscience diseases. It serves patients worldwide with leading therapies such as Eliquis, Opdivo, Revlimid, Orencia, and Yervoy.
BMY is set to unveil its fiscal Q4 2025 results before the market opens on Thursday, Feb. 5. Ahead of this event, analysts expect the Princeton, New Jersey-based company to report an adjusted EPS of $1.65, down 1.2% from $1.67 in the year-ago quarter. However, it has surpassed Wall Street's bottom-line estimates in the past four quarters.
More News from Barchart
-
Netflix Stock Is Beaten Down - But Short Put Plays Are Attractive
-
D-Wave Just Got a ‘Formidable’ Quantum Computing ‘Ally.’ Should You Buy QBTS Stock Here?
-
Earnings Kickoff, CPI and Other Can't Miss Items this Week
-
Stop Missing Market Moves: Get the FREE Barchart Brief – your midday dose of stock movers, trending sectors, and actionable trade ideas, delivered right to your inbox. Sign Up Now!
For fiscal 2025, analysts project the biopharmaceutical giant to report adjusted EPS of $6.53, a surge of 467.8% from $1.15 in fiscal 2024.
www.barchart.com BMY stock has declined 1.7% over the past 52 weeks, lagging behind the S&P 500 Index's ($SPX) 17.7% gain and the State Street Health Care Select Sector SPDR ETF's (XLV) 12% rise over the same period.
www.barchart.com Shares of Bristol Myers Squibb climbed 7.1% on Oct. 30 after the company reported stronger-than-expected Q3 2025 adjusted EPS of $1.63 and revenue rising 3% to $12.2 billion. Investor sentiment was further boosted by 18% Growth Portfolio revenue growth to $6.9 billion, driven by strong performance from its immuno-oncology portfolio, Reblozyl, Camzyos, and Breyanzi. The company also raised its full-year 2025 revenue guidance to $47.5 billion - $48 billion and updated adjusted EPS guidance to $6.40 - $6.60.
Analysts' consensus rating on BMY stock is moderately optimistic, with a "Moderate Buy" rating overall. Out of 29 analysts covering the stock, opinions include nine "Strong Buys,” one "Moderate Buy," 18 "Holds," and one "Strong Sell.” As of writing, it is trading above the average analyst price target of $56.17.
On the date of publication, Sohini Mondal did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Barchart.com
Terms and Privacy Policy Privacy Dashboard More Info